CELL — Phenomex Income Statement
0.000.00%
HealthcareHighly SpeculativeSmall Cap
- $98.79m
- $67.83m
- $78.60m
Annual income statement for Phenomex, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 31.3 | 56.7 | 64.3 | 85.4 | 78.6 |
Cost of Revenue | |||||
Gross Profit | 23.1 | 43.5 | 44.6 | 56.6 | 53.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 52.5 | 73.2 | 105 | 156 | 177 |
Operating Profit | -21.2 | -16.5 | -40.4 | -70.8 | -98.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.3 | -18.2 | -41.4 | -71.8 | -97.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.3 | -18.3 | -41.6 | -71.7 | -98 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.3 | -18.3 | -41.6 | -71.7 | -98 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.5 | -21.5 | -43.3 | -71.7 | -98 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.423 | -0.34 | -0.657 | -1.07 | -1.39 |
Dividends per Share |